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1. Introduction 
Therapy with implantable cardioverter-defibrillators (ICDs) has been shown to improve 
survival among several large groups of patients at risk for sudden cardiac death (SCD). 
Several complicating issues arose from the widespread use of ICDs especially in heart 
failure (HF) patients. Twenty percent to 35% of HF patients who receive an ICD for primary 
prevention of SCD will receive an appropriate shock within 1 to 3 years for a life-threatening 
arrhythmia.1 Almost half of the HF patients who survive a cardiac arrest and receive an ICD 
for secondary prevention will receive a shock within 1 year of implant.2 Implantable 
cardioverter-defibrillator (ICD) shocks are usually regarded with a sense of relief given that 
the ventricular tachyarrhythmia was treated, and the SCD was averted. There is, however, 
accumulating data from the literature showing that patients with ICDs who receive shocks, 
whether appropriate or spurious, have worse prognosis than similar patients who do not 
receive shocks.  
Current guidelines do not provide a clear approach to managing patients presenting with 
ICD shocks, who clearly represent a high-risk group. However, current data from the 
literature suggest that ICD shocks should prompt a thorough evaluation to determine the 
etiology of the shock and to help guide therapeutic interventions. 
2. Initial evaluation after ICD discharge 
The initial evaluation of the patient who receives an ICD shock begins with interrogation of 
the device. The timing of the device interrogation depends on the number of shocks and 
related symptoms.3 In case of an isolated shock without change in clinical status or 
symptoms, evaluation should generally occur within a few days.4 Multiple ICD shocks or 
shocks associated with worsening HF symptoms, syncope, angina, or electrical storm 
warrant emergent medical attention.4 
Device interrogation will reveal whether the ICD shock was appropriate or inappropriate. 
While there is still some debate regarding the definition of an appropriate shock, most 
authors agree that any shock for ventricular tachycardia (VT) or ventricular fibrillation (VF) 
is considered appropriate.  
The acute management strategies depend on the specific etiology of the shock. If the shock 
was appropriate the next step is to address reversible causes, check and correct electrolytes, 
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consider antiarrhythmic therapy, optimize betablocker treatment, optimize device therapies 
including antitachycardia pacing (ATP), and consider intubation and sedation for refractory 
VT or VF. If the shock was inappropriate the acute strategy is to treat the supraventricular 
tachycardia, optimize device programming, and assess for possible lead oversensing.3 
In addition to all these acute management strategies it is important to realize that even 
though the SCD might have been prevented by the ICD shock, the natural history of the 
disease is now transformed and there is accumulating data suggesting that the prognosis of 
the group of patients who receive shocks, especially in HF patients, is worse than the rest of 
the ICD patients.  
3. Appropriate ICD shocks 
3.1 Prognostic importance of appropriate ICD shocks  
Several large trials have shown that therapy with ICDs improves survival among patients 
who are at risk for SCD.3, 5, 6 Based on these results the implantation of an ICD for primary 
prevention has become standard of care for patients who meet the high-risk criteria.7 One 
potential result of the broader use of ICDs is that the natural history of the disease in these 
patients is modified as a consequence of the delivery of ICD therapies. The results of the 
MADIT II were the first to demonstrate an adverse prognosis associated with ICD therapy 
used for primary prevention.8, 9 In this study, among 719 patients with ischemic heart 
disease, an ICD shock or antitachycardia pacing was reported to be appropriate in 23.5%. 
The risk of death, was found to be increased by a factor of more than 3 among patients who 
received ICD shocks or antitachycardia pacing for ventricular tachycardia or ventricular 
fibrillation.8  
After an ICD shock for a life-threatening arrhythmia, hospitalizations for HF were more 
frequent, and mortality was increased 3-fold.10 Within one year of an ICD shock for 
ventricular tachycardia (VT) or ventricular fibrillation (VF), the probability of an HF event 
was 26% and 31%, respectively, while it was 19% for those not having an ICD.10 The 
corresponding survival rate one year after initial ICD shock for VT or VF was 80% and the 
survival curves were related to the rate of the presenting tachycardia. Increased tachycardia 
rates were associated with lower survival rates. Other clinical factors associated with 
increased mortality after appropriate ICD discharge, were blood urea nitrogen, lack of beta-
blockade, NYHA functional class, presence of atrial fibrillation (AF), and diabetes mellitus.10 
The ICD therapy was associated with a 39% increased risk of a first HF hospitalization and a 
58% increase in recurrent admission for HF.10 
Analysis of data from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)1 
showed findings consistent with those of the MADIT-II study.3 In the SCD-HeFT study, 
33% of HF patients received an ICD shock. Among these patients treated with ICD 
discharges the most common cause of death was progressive HF. Patients receiving an 
appropriate shock had a 5-fold increase in risk of death, whereas patients receiving an 
inappropriate shock had a 2-fold increase in risk of death. Multiple shocks increased the 
risk of death more than single shocks. The median time from shock to death was 168 days 
among patients receiving appropriate shocks and 294 days among patients receiving 
inappropriate shocks.3  
The risk of death with appropriate ICD shocks was higher in the study by Poole et al. 1 - 
increased by a factor of more than 5. The higher risk of death associated with appropriate 
ICD shocks found by Poole and colleagues in comparison to the MADIT II study may be 
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related to the longer follow-up and the exclusion of patients with NYHA class I disease 
(selection of patients with higher risk than those in MADIT II). In addition these results 
reflect the use of primarily single-lead ICDs, a single zone of therapy, and shock-only 
programming for high-rate arrhythmias that were most likely to be life-threatening.1 Similar 
to MADIT-II patients, SCD-HeFT patients with NYHA functional class III and ischemic 
cardiomyopathy had a shorter duration between initial shock and death. Subgroup analyses 
from MADIT-II trial confirm that ICD shocks increase the risk for first and recurrent HF 
events.2, 10  
One of the most important questions generated by these results is why ICD patients tend to 
have worsening prognosis and more frequent HF after an ICD shock. Myocardial damage 
induced by ICD shocks may contribute to worsening HF.11, 12 This is suggested by the adverse 
impact on prognosis of inappropriate shocks. In the MADIT-II study, however, inappropriate 
shocks did not increase the risk of adverse outcomes. In the study by Poole and colleagues, 
mortality after an inappropriate shock was approximately 3-fold less than after appropriate 
therapy, thus downplaying the role of shock-induced myocardial damage contributing to HF 
risk, and suggesting that arrhythmia may simply be a marker of worsening HF.3  
In an editorial comment on the study of Poole et al., Healey and Connolly surmised the 
situation as follows: “Although it is plausible that shocks somehow have an adverse effect on 
myocardial function, this is unlikely to be a major factor. What is much more likely is that the 
occurrence of a ventricular arrhythmia that causes a shock is signaling a meaningful change in 
the patient’s clinical status….occurrence of shocks is not a random event in an otherwise stable 
clinical course but a sign of clinical deterioration in the underlying disease process.”44 We 
concur with this opinion. Furthermore, inappropriate ICD discharges, which largely result 
from atrial fibrillation or other rapidly conducting supraventricular tachycardias may be 
associated with higher subsequent mortality because they too, though to a lesser degree than 
ventricular tachyarrhythmias, signify underlying electrical and/or structural abnormalities 
that negatively impact the prognosis of those patients who experience them compared to those 
who do not. 
Another interesting hypothesis is that right ventricular pacing with a dual-chamber ICD 
may contribute to increased HF risk after ICD implant.13 In the MADIT-II study, however, 
the risk of HF events was similar whether patients received a single- or dual-chamber ICD 
despite differences in right ventricular pacing (92% of patients with single-lead ICDs had no 
pacing, whereas 66% of patients with dual-chamber ICDs had cumulative RV pacing 
exceeding 50%).3 Even if right ventricular pacing has a certain contribution to the adverse 
outcomes, the increased risk of HF after ICD implantation cannot be solely due to right 
ventricular pacing.3  
These findings suggest that, in HF patients, an ICD shock is associated with a 2-to 5-fold 
increase in mortality, most commonly due to progressive HF.1 It is not known whether the 
arrhythmia leading to ICD shock is a marker for worsening HF or whether the shock itself 
leads to worsening HF. Regardless of the individual factors causing greater HF events in 
current ICD populations, there appear to be multiple triggers that, when combined with 
high-risk patients, cause an increased HF risk. Heart failure patients with high-risk features 
such as NYHA functional class III, atrial fibrillation (AF), and ischemic cardiomyopathy 
require closer observation and management after ICD shock as sudden death risk is now 
transformed to an increased HF event risk.3 
It is unknown whether the increase in risk in association to the appropriate ICD shocks is 
due to the ventricular arrhythmia (VA) or shocks and whether anti-tachycardia pacing 
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(ATP) termination can reduce this risk. To determine whether mortality in ICD patients is 
influenced by the type of therapy (shocks or ATP) delivered, Sweeney et al. evaluated the 
effects of baseline characteristics, VT, fast VT (FVT, 188–250 bpm), VF, and therapy type 
(shocks or ATP) on mortality among 2135 patients in four trials of ATP to reduce shocks.14 
The results revealed that patients with VA episodes and shocks have higher mortality (20% 
increased risk per shocked episode) than patients with neither or patients with VA treated 
only with ATP. In addition patients with more VA episodes and more shocks have higher 
mortality than patients with less of both. Interestingly, in this study, inappropriate shocked 
episodes were not associated with increased mortality risk. There are three potential 
explanations for these findings: (a) electrical trauma from shocks, but not ATP, increases 
risk; (b) VA episodes increase mortality risk irrespective of terminating therapy; (c) VA 
episodes and the shocks, but not ATP, increase mortality risk.14 Interactions between 
adverse shock effects are possible for scenarios (a) and (c) such that patients with more VA 
episodes may be more susceptible to harm from shocks. When electrical therapy type was 
included in the statistical analysis, ATP-terminated VT and shocked VF remained significant 
predictors of death. However, the risk in either case was indistinguishable from the risk 
unqualified for therapy (4% for VT vs. 3% for VT  ATP; 15% for VF vs. 16% for VF  shocks) 
and uncoupling the mortality effect of therapy type from episode type was impossible. 
Therefore, it was not possible to conclude that shocks for VT are harmful and that ATP is 
harmless or that shocks for VF increase episode risk.14 However, since 1/3 of FVT episodes 
were shocked and 2/3 ATP terminated, episode and therapy type mortality effects could be 
statistically uncoupled. FVT treated with ATP only was not associated with increased risk of 
death, whereas similar FVT episodes that were shocked increased the risk of death by 32% 
suggesting that shocks are associated with increased risk and ATP is not.14 The majority of 
shocks (60%) were for FVT, and 72% of shocked patients had at least one shock for FVT, 
making shocked FVT the most prevalent type of shocked episode and the dominant shock 
effect in the mortality models. Most shocks that were delivered in this study were for FVT 
and occurred at a 12 times higher rate among patients who died, whereas shocks for VF 
occurred at a 8 times higher rate.  
Time spent in VA was 7 times higher per month among patients who died, and episode 
durations were higher for all episode/therapy combinations and greatest for shocked 
episodes preceded by failed ATP (22-fold increase). In addition to receiving more shocks, 
patients who died had longer duration shocked episodes (including failed ATP) and spent 
more time in shocked episodes compared with survivors. It is possible that longer episode 
durations after failed ATP magnify the adverse effect of shocks.14  
In summary, the results from the study of Sweeney et al. confirm that shocks are associated 
with increased risk of adverse outcomes while ATP is not. This is consistent with data from 
MADIT II where ATP, unlike shocks, was not associated with increased risk of death.16 
3.2 Possible mechanisms for increased risk of negative outcomes associated with 
appropriate ICD shocks 
The idea that shocks are associated with risk of death and HF in ICD patients is not new. A 
commonly held interpretation is that VA is a marker for clinical deterioration, shocks are 
harmless, and the increased risk reflects progression of the myocardial disease.1, 14, 17  
An alternative explanation is that shocks may causally increase risks of HF and death. In 
MADIT II, the risk of first and recurrent HF hospitalization increased by 90% and 74%, 
respectively, after appropriate shocks.10 Survival after the first appropriate shock was 80% at 
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1 year. This was significantly less than the survival before the first shock, and the 
nonsudden cardiac death rate increased 17%.8 
Shock-related myocardial injury has been investigated extensively. Large shock field 
strengths destroy cardiac myocytes causing biomarker release, which increases with shock 
strength and proximity to recent MI.11, 12, 18 The severity of post-resuscitation myocardial 
depression increases with shock strength, and is inversely related to survival.19 Repetitive 
shocks may cause cardiovascular collapse and death due to electromechanical 
dissociation.14  
One reasonable hypothesis would be that the specific type of the arrhythmia episode may 
precondition the myocardium to the adverse effects of shocks and that factors unique to 
spontaneous ventricular arrhythmias magnify these effects, particularly in ATP-
unresponsive ventricular episodes.  
Investigations of shock-related myocardial injury have focused on acute effects that may be 
insufficient to account for reduced survival after appropriate shocks.14 Other mechanisms 
may be important. Shocks may activate signaling pathways in the molecular cascade of HF. 
The clinical consequence may manifest months after shocks. 
In contrast to the data on ICD shocks, there is no evidence that ATP has adverse cardiac 
effects. ATP termination of VT or FVT, unlike shocks, does not cause biomarker release 20 or 
reduce ventricular pump function.21  
3.3 Clinical implications 
Twenty-two percent to 35% of patients will receive appropriate ICD therapy for VT or VF 
within 3 years of implant, with an annual ICD shock rate of 5%.1, 3, 8 Despite the possible 
increase risk of death and HF with shocks, ICDs prolong survival.14 Near total reliance on 
shocks may have underestimated the ICD survival benefit in the above-mentioned clinical 
trials. The SCD-HeFT study was designed to provide ICD therapy that consisted of shock-
only, single lead therapy for rapid, sustained VT or VF. No dual chamber or ATP therapy 
was allowed.3 The incidence of appropriate shock for VT or VF was 22.4%. Sixty-seven 
percent of patients received no ICD therapy. In the MADIT-II study, dual-chamber devices 
were used with the capability of ATP or shock therapy. 
Since VF can only be terminated with shocks, uncoupling therapy from episode risk could 
be indirectly addressed with graded shock energies.14 Strategies to minimize shocks by 
using ATP as first line device therapy when possible,22 decrease shock energies, and reduce 
the burden of ventricular arrhythmias by using antiarrhythmic drugs and substrate 
modification may further improve survival in ICD patients.14 There are several other 
strategies that were proven effective in reducing device shocks. In a recent study by Desai 
and colleagues In the present study of 549 patients with heart failure and ICDs, smoking 
significantly increased the incidence of appropriate ICD shocks 3.7 times, and the use of 
statins significantly reduced appropriate ICD shocks by 46%.23 This is consistent with 
previous results from the MADIT II trial.24, 25  
4. Inappropriate ICD shocks 
Inappropriate ICD discharges result from the inability to distinguish supraventricular  from 
ventricular arrhythmias, abnormal arrhythmia sensing or mechanical problems such as lead 
fracture, insulation break, and lead dislodgement. The  shocks are painful, psychologically 
disturbing, potentially arhythmogenic and possibly associated with worse survival. 
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4.1 Incidence, mechanisms, and predictors of inappropriate shocks 
An important contribution to the literature on the epidemiology of inappropriate ICD 
therapy was provided by the investigators of  the MADIT II trial.16 The authors reported an 
incidence of inappropriate shocks of 11.5 % with a cumulative 1 and 2 year event rate of 10% 
and 13% respectively.16 In other studies such as AVID, PainFREE Rx, SCD-HeFT the 
incidence of inappropriate shocks was reported to be 20%, 15% and 32% respectively.1, 26 
The MIRACLE ICD study reported an incidence of inappropriate detection of 32% but not 
all detections resulted in an ICD discharge. Although the incidence of inappropriate ICD 
shocks was found to be somewhere between 10% and 35% in all the studies available in 
literature, the ratio of inappropriate ICD shocks over the appropriate shocks varies widely 
depending on the population that was studied. The highest ratio is expected to occur in 
patients who receive ICDs for primary prevention where the incidence of appropriate ICD 
shocks is relatively low. The majority of these patients experience the first inappropriate 
shock after a mean period of 17±15 months from the device implantation. The cumulative 
percent rate was found to be around 7% at 1 year, 13% at 3 years and 18% at 5 years. 
Approximately a third of the patients who receive one inappropriate shock typically receive 
the second one after a mean period of 11±11 months with the cumulative event rate of 28%, 
49%, and 55% at 1 year, 3 years and 5 years respectively after the first shock.27 
The most common causes of inappropriate ICD shocks are supraventricular tachycardia 
episodes and inappropriate sensing. Of all supraventricular tachycardias, AF with rapid 
ventricular response is the most common cause of an inappropriate ICD shock. This occurs 
because most ICDs are programmed to recognize VT when the heart rate exceeds a 
threshold value and SVTs may do so. Device companies have developed algorithms by 
which ICDs may differentiate VT from SVT using such parameters as sudden onset, rhythm 
stability and electrogram template matching. These strategies have demonstrated little 
impact in reducing discharges for SVT in part due to limited rhythm discrimination, because 
VT and SVT can mimic each other, and in greater part because they are probably little 
utilized by programming physicians. 
Atrial fibrillation (AF) is a common finding in patients with low left ventricular ejection 
fraction and HF symptoms. Among HF patients, AF can occur with a prevalence of as high 
as 50% in patients with New York Heart Association (NYHA) functional class IV. Patients 
with HF and ICDs who also have AF have a significantly higher risk of experiencing 
inappropriate ICD shocks than patients without AF. Furthermore, patients with permanent 
AF seem to have doubled risk of developing an inappropriate shock, and patients with 
paroxysmal or persistent AF are exposed to a tripled risk of developing inappropriate ICD 
shocks when compared with the patients without any history of AF. 
There are other risk factors for inappropriate shocks in addition to supraventricular 
tachyarrhythmias. Age younger than 70 years, nonischemic cardiomyopathy, non-use of 
statins, smoking, and interim appropriate ICD shocks were reported to be independent 
predictors of inappropriate ICD shocks.16, 24, 29  
The MADIT II trial data analysis as well as other recent studies shows a significant 3-fold 
increase in the risk of inappropriate ICD shocks among current smokers. The overall risk of 
inappropriate ICD therapy was significantly increased among current smokers (20%) 
compared to past smokers (14%) and patients who never smoked (11%). This difference was 
mainly due to the increased numbers of ICD shocks in the current smokers group. The main 
causes of the ICD shocks in these groups were supraventricular tachycardia and sinus 
tachycardia, which were more frequent in current smokers than in past and never-smokers. 
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Tobacco smoke causes sympathetic stimulation as well as increased platelet reactivity and 
endothelial dysfunction, tachycardia and high blood pressure, all of these leading to 
supraventricular tachycardia which could potentially induce inappropriate ICD shocks.1, 24  
In some cases the treatment for ventricular arrhythmias can precipitate AF and initiate an 
inappropriate ICD discharge. An inappropriate therapy itself causing VT can lead to an 
appropriate ICD discharge as well. Most of the patients who received an ICD for VT or VF 
have predisposing factors that are common for VT and AF, which also makes them more 
prone in developing AF and increases their risk of inappropriate discharge. 30, 31 
Recent studies have demonstrated that patients younger than seventy years old are at 
increased risk for experiencing inappropriate ICD shocks24 due chiefly to sinus tachycardia 
episodes.27 
One study has demonstrated that the cause of inappropriate shocks is partly dependent on 
the number of ICD leads. Patients with single chamber devices received more shocks for 
sinus tachycardia compared to those with dual chamber units (28% vs 8%) ,whereas  
patients with CRT devices received more shocks due to abnormal sensing compared to 
patients with single chamber ICDs (15% vs. 8 %).27 
4.2 Prognostic importance of inappropriate ICD shocks 
Data from ICD trials have demonstrated that inapropriate ICD discharges may compund 
the prognostic risk of appropriate shocks. Poole et al. found that among patients who 
received ICDs for primary prevention of SCD the risk of death doubled when inappropriate 
shocks were delivered in comparison to patients who did not receive shocks at all.1 A 
patient who received an appropriate shock and an inappropriate shock has a risk of death 
increased by a factor of 11 when compared with a patient who received no shock at all. The 
patients who received at least two previous appropriate shocks and have received an 
inappropriate shock have a risk of death increased by 15 and additional inappropriate 
shocks do not result in further increase in the risk of death. Similar findings were reported 
in the MADIT II trial. Although previous studies reported appropriate shocks to be 
predictors of future CHF hospitalizations, in the MADIT II trial the inappropriate shocks did 
not predict future hospitalizations.16  
It is uncertain why an inappropriate shock is associated with an increase in mortality. One 
possible explanation could be the fact that the development of AF, the most common cause 
of an inappropriate shock, in a patient with heart failure carries a worse prognosis.32 
Benjamin et al. showed that the occurrence of AF was associated with a 1.5 to 1.9-fold risk of 
all-cause mortality.32 These findings were confirmed also in an ICD population by Borleffs 
and colleagues who found a 1.7 times increased risk of mortality in patients with permanent 
AF when compared with non-AF population. The highest mortality is shown by the patients 
who have permanent atrial fibrillation followed by those with persistent atrial fibrillation 
and then by patients with paroxysmal atrial fibrillation. 28 
Other causes that could explain the increase in mortality could be explained by the direct 
effect of the shocks on the myocardium. The presence of positive cardiac markers after 
inappropriate discharge suggests that the shock causes myocardial damage leading to 
ventricular dysfunction.28, 33 Shocks with higher energy delivered are more likely to cause 
more myocardial damage. Tokano and colleagues demonstrated that shocks with energy 
greater than 9 J cause a 10% to 15% transient reduction of the cardiac index. The duration 
and the extent of the effect are proportional to the shock strength. The detrimental  
www.intechopen.com
Cardiac Defibrillation  
– Prediction, Prevention and Management of Cardiovascular Arrhythmic Events 
 
48
homodynamic effect of a ventricular defibrillator shock appears to be due to the shock itself, 
and not to ventricular fibrillation. The latest conclusion was drawn from the observation 
that a similar degree of ventricular stunning was noted after shocks delivered during the 
baseline rhythm as with shocks that terminated ventricular fibrillation.34 
4.3 Impact on psychology and life style 
Delivery of an ICD shock, is often associated with increased psychological distress in 
patients and their families.35, 36 The AVID trial extended these findings by demonstrating 
that patients who received more than one ICD shock within the initial year of implantation 
reported significant declines in physical functioning and mental well being.37 Increased 
sadness, anxiety, fatigue, and nervousness were also found to be associated with more ICD 
discharges38 Other studies reported that overall psychological distress was significantly 
correlated with the total number of ICD shocks a patient receives.39  
4.4 Clinical implications 
Ever since ICD therapy was developed technology improved constantly including the 
ability to differentiate supraventricular from ventricular tachyarrhythmias and to prevent 
inappropriate discharges. In spite of all the progress been made, recent research that 
assessed the incidence of inappropriate shocks in the ICDs implanted recently in 
comparison to those implanted a while ago did not show any improvement even more than 
that it appeared that the patients who received the ICDs more recently are exposed to a 
greater risk of developing an inappropriate shock. This phenomenon is mostly explained by 
the fact that guidelines for ICD implantation keep changing, shifting more towards primary 
prevention. The primary prevention group is represented by patients who usually have a 
more advanced underlying cardiac disease, which exposes them to a higher risk of 
developing AF, which is the number one cause of inappropriate discharge.33 Criteria 
incorporated in the modern ICD algorithms used to discriminate ventricular from 
supraventricular tachycardia include rapidity of onset of the arrhythmia and QRS 
morphology.40 Discriminating algorithms typically increase the specificity but at the same 
time they decrease the sensitivity for VT recognition.41  
Despite widespread use of antiarrhythmic medications in patients with ICDs there are only 
a few studies documenting the efficacy of these therapies in this patient population. Sotalol 
and dofetilide when used as antiarrhythmic agents in patients with ICDs were found to 
reduce the risk of inappropriate shocks.42, 43 Amiodarone was also found to be effective in 
preventing inappropriate shocks in patients with ICDs but it has a significant number of 
side effects and can lead to elevation of the defibrillation threshold (DFT).  
In addition, the β-adrenergic blocking agents are efficacious antiarrhythmic drug therapies 
and can be effective in reducing the incidence of both supraventricular and ventricular 
arrhythmias in ICD patients. 
Finally, trying to address other identifiable predictors of innapropiate shocks might be beneficial 
in terms of reducing both appropriate and inappropriate shocks: smoking cessation, treating 
illnesses that can cause sinus tachycardia, starting the patient on a statin if appropriate. 
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